Rare Cell Analysis Using Sample Splitting And DNA Tags
The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample.
1 . (canceled)
2 . A method for determining a presence or absence of a fetal aneuploidy of a fetus in a maternal blood sample from a woman who is pregnant or who is suspected of being pregnant, the method comprising:
(a) obtaining a mixture of fetal and maternal cells from the maternal blood sample and dividing the mixture into discrete locations such that no more than one cell is located per discrete location;
(b) obtaining genomic DNA from fetal cells or maternal cells located within the discrete locations;
(c) conducting multiplex polymerase chain reaction (PCR) to amplify target regions in the genomic DNA to obtain amplified nucleic acid molecules, wherein each amplified nucleic acid molecule comprises a tag that identifies the nucleic acid molecule as coming from a specific discrete location;
(d) pooling the amplified nucleic acid molecules with tagged amplicons from at least one other multiplex PCR;
(e) conducting quantitative genotyping to quantify DNA regions of at least one chromosome being tested for aneuploidy and of at least one control chromosome that is presumed to be diploid; and
(f) determining the presence or absence of a fetal aneuploidy for the at least one chromosome being tested for aneuploidy from quantification of the chromosomal DNA regions of step (e).
3 . The method of claim 2 , wherein the fetal aneuploidy is segmental aneuploidy.
4 . The method of claim 2 , wherein the fetal aneuploidy comprises monosomy, trisomy, tetrasomy, or pentasomy of one or more chromosomes.
5 . The method of claim 4 , wherein the one or more chromosomes are sex chromosomes.
6 . The method of claim 4 , wherein the fetal aneuploidy comprises trisomy.
7 . The method of claim 6 , wherein the trisomy comprises trisomy 13, trisomy 18, or trisomy 21.
8 . The method of claim 4 , wherein the fetal aneuploidy comprises monosomy, and wherein the monosomy comprises monosomy X.
9 . The method of claim 2 , wherein the at least one chromosome being tested for aneuploidy is selected from the group consisting of chromosome 13, chromosome 18, chromosome 21, chromosome X, and chromosome Y.
10 . The method of claim 2 , wherein the tag comprises a sequencing element.
11 . The method of claim 10 , wherein the sequencing element is about 4, 6, 8, 10, 18, 20, 28, 36, 46, or 50 nucleotide bases in length.
12 . The method of claim 10 , wherein the quantitative genotyping comprises sequencing-by-synthesis initiated using sequencing primers complementary to the sequencing element.
13 . The method of claim 12 , wherein the sequencing-by-synthesis involves synthesizing nucleic acid strands complementary to the amplified nucleic acid molecules and inferring nucleic acid sequences of the amplified nucleic acid molecules from the complementary synthesized nucleic acid strands.
14 . The method of claim 12 , wherein the sequencing-by-synthesis comprises detecting an identity of each nucleotide immediately after or upon incorporation of a labeled nucleotide or nucleotide analog into a growing nucleic acid strand complementary to the amplified nucleic acid molecules.
15 . The method of claim 2 , wherein the DNA regions comprise polymorphisms and wherein the computer executable logic fits data of a quantity of allele abundance for each polymorphism into one or more data models.
16 . The method of claim 2 , wherein the quantitative genotyping comprises ultra-deep sequencing, wherein the ultra-deep sequencing comprises further amplification of the amplified nucleic acid molecules to produce at least one million copies of individual amplified nucleic acid molecules in parallel.
17 . The method of claim 16 , wherein the further amplification comprises bridge amplification.
18 . The method of claim 16 , wherein the further amplification comprises whole genome amplification or rolling circle amplification.
19 . The method of claim 2 , wherein the DNA regions comprise short tandem repeats (STRs) or single nucleotide polymorphisms (SNPs), or both, and wherein the ultra-deep sequencing is used to provide an accurate and quantitative measurement of the allele abundances for each STR or each SNP.